A Great Deal....i. Vote for the deal...
Do Not listen to Wellington or starboard, they have no arguments, bullshit only to oppose the deal.
It was a bargain for BMY and together there is Avery strong company.
I agree with:
BMY after merger will have a market leading oncology portfolio in BOTH solid tumors and hematologic malignancies led by Opdivo and Yervoy along with Revlimid and Pomalyst. The cardiovascular, immunology and inflammation franchise will be strengthened with the presence of Eliquis, Orencia and Otezla, respectively. Moreover, with BMY and Celg combined, the new entity will also have a deep pipeline including six expected near-term product launches with potential sales of $25 billion